Xencor (NASDAQ:XNCR) Posts Earnings Results, Misses Expectations By $1.06 EPS

Xencor (NASDAQ:XNCR) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($1.06), FiscalAI reports. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million.

Xencor Stock Performance

Shares of Xencor stock traded up $0.16 on Wednesday, reaching $13.01. 814,405 shares of the stock were exchanged, compared to its average volume of 781,273. Xencor has a 1-year low of $6.92 and a 1-year high of $18.69. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The business has a fifty day moving average price of $12.24 and a two-hundred day moving average price of $13.63. The firm has a market capitalization of $964.43 million, a PE ratio of -10.49 and a beta of 0.93.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 4,118 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $46,327.50. Following the transaction, the vice president directly owned 266,333 shares in the company, valued at $2,996,246.25. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bassil I. Dahiyat sold 14,870 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $167,287.50. Following the transaction, the chief executive officer owned 552,922 shares in the company, valued at approximately $6,220,372.50. This trade represents a 2.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,020 shares of company stock worth $499,817 over the last ninety days. 5.23% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its position in Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares during the period. E Fund Management Co. Ltd. acquired a new position in Xencor during the second quarter worth about $79,000. Norges Bank acquired a new position in Xencor during the fourth quarter worth about $175,000. Prelude Capital Management LLC acquired a new position in Xencor during the third quarter worth about $139,000. Finally, Entropy Technologies LP acquired a new position in Xencor during the fourth quarter worth about $183,000.

Analysts Set New Price Targets

XNCR has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. Wall Street Zen raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Barclays upped their target price on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 target price (down from $18.00) on shares of Xencor in a report on Tuesday, March 24th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xencor has a consensus rating of “Moderate Buy” and a consensus target price of $24.38.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.